-0.02 | -0.78%
| Price and Volume | |
|---|---|
| Recent Price | 2.56 |
| 52 Week High | 5.39 |
| 52 Week Low | 1.44 |
| Avg. Daily Vol. (Mil) | 1.93 |
| Beta (3 year) | 1.61 |
| Share Related Items | |
| Mkt Cap (Mil) | 111.03 |
| Shares Out (Mil) | 43.37 |
| Float (Mil) | 42.88 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 3.80 |
| Current Ratio | 3.80 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.01 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 552.39 |
| Price/Book | 2.63 |
| Price/Cash Flow | -4.30 |
| Per Share Data | |
| Earnings | -1.09 |
| Sales | 0.00 |
| Book Value | 0.97 |
| Cash Flow | -0.60 |
| Business Summary | |
|---|---|
| Discovery Laboratories, Inc. is engaged in the development of Surfactant Replacement Therapies (SRT) to treat respiratory disorders and diseases for which there frequently are few or no approved therapies. | |
| General Information | |
| 2600 Kelly Road
Suite 100 Warrington, PA 18976-3622 |
|
| www.discoverylabs.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 70 | |
| CEO: W. Thomas Amick | |
| Short Interest | |
| Current Month (Mil) | 1.91 |
| Previous Month (Mil) | 1.80 |
| Short Interest Ratio (Days) | 2.30 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -47.00 |
| Return on Investments | -64.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,528.09 | 1,324.88 | 2,853.29 | 17.14 |
Oil *
106.56
|
|
UP
73.26 |
UP
7.06 |
UP
15.76 |
DOWN
0.31 |
10 Yr
1.71%
SPDR Gold
151.19
|
|
+0.59%
|
+0.54%
|
+0.56%
|
-1.78%
|
Data delayed 20 minutes |
Connect with TheStreet